Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
Status:
RECRUITING
Trial end date:
2029-11-10
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of the Glofitamab bridging ASCT regimen in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and to provide better clinical benefits to these patients.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University